These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 22704893)

  • 61. Landmark analysis: A primer.
    Morgan CJ
    J Nucl Cardiol; 2019 Apr; 26(2):391-393. PubMed ID: 30719655
    [No Abstract]   [Full Text] [Related]  

  • 62. Landmark in cancer research.
    ANDREWES CH
    Caribb Med J; 1949; 11(3):108-10. PubMed ID: 15408306
    [No Abstract]   [Full Text] [Related]  

  • 63. Landmark in cancer research.
    ANDREWES CH
    Med Times; 1949 Nov; 77(11):495. PubMed ID: 15395638
    [No Abstract]   [Full Text] [Related]  

  • 64. Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation.
    Hasan B; Greillier L; Pallis A; Menis J; Gaafar R; Sylvester R; Fennell DA; Baas P; Surmont V; Van Meerbeeck JP; O'brien ME
    Eur J Cancer; 2014 Nov; 50(16):2771-82. PubMed ID: 25155251
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Fully automated volumetric measurement of malignant pleural mesothelioma by deep learning AI: validation and comparison with modified RECIST response criteria.
    Kidd AC; Anderson O; Cowell GW; Weir AJ; Voisey JP; Evison M; Tsim S; Goatman KA; Blyth KG
    Thorax; 2022 Dec; 77(12):1251-1259. PubMed ID: 35110367
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Inherited Genetic Mutations and Polymorphisms in Malignant Mesothelioma: A Comprehensive Review.
    Panou V; Røe OD
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560575
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.
    Hassan R; Morrow B; Thomas A; Walsh T; Lee MK; Gulsuner S; Gadiraju M; Panou V; Gao S; Mian I; Khan J; Raffeld M; Patel S; Xi L; Wei JS; Hesdorffer M; Zhang J; Calzone K; Desai A; Padiernos E; Alewine C; Schrump DS; Steinberg SM; Kindler HL; King MC; Churpek JE
    Proc Natl Acad Sci U S A; 2019 Apr; 116(18):9008-9013. PubMed ID: 30975761
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Chemosensitivity and resistance testing in malignant effusions with focus on primary malignant mesothelioma and metastatic adenocarcinoma.
    Szulkin A; Szatmári T; Hjerpe A; Dobra K
    Pleura Peritoneum; 2016 Sep; 1(3):119-133. PubMed ID: 30911616
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma.
    Mansfield AS; Peikert T; Vogelzang NJ; Symanowski JT
    Mayo Clin Proc; 2018 Aug; 93(8):1026-1033. PubMed ID: 29804728
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response.
    Rahouma M; Aziz H; Ghaly G; Kamel M; Loai I; Mohamed A
    Asian Pac J Cancer Prev; 2017 Aug; 18(8):2073-2078. PubMed ID: 28843224
    [TBL] [Abstract][Full Text] [Related]  

  • 71. First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.
    Angevin E; Isambert N; Trillet-Lenoir V; You B; Alexandre J; Zalcman G; Vielh P; Farace F; Valleix F; Podoll T; Kuramochi Y; Miyashita I; Hosono O; Dang NH; Ohnuma K; Yamada T; Kaneko Y; Morimoto C
    Br J Cancer; 2017 Apr; 116(9):1126-1134. PubMed ID: 28291776
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions.
    Szulkin A; Otvös R; Hillerdal CO; Celep A; Yousef-Fadhel E; Skribek H; Hjerpe A; Székely L; Dobra K
    BMC Cancer; 2014 Sep; 14():709. PubMed ID: 25253633
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo.
    Manente AG; Valenti D; Pinton G; Jithesh PV; Daga A; Rossi L; Gray SG; O'Byrne KJ; Fennell DA; Vacca RA; Nilsson S; Mutti L; Moro L
    Oncogenesis; 2013 Sep; 2(9):e72. PubMed ID: 24061575
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy.
    Szulkin A; Nilsonne G; Mundt F; Wasik AM; Souri P; Hjerpe A; Dobra K
    PLoS One; 2013; 8(6):e65903. PubMed ID: 23840376
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma.
    Blayney JK; Ceresoli GL; Castagneto B; O'Brien ME; Hasan B; Sylvester R; Rudd R; Steele J; Busacca S; Porta C; Mutti L; O'Byrne KJ; Scullin P; Gaafar R; Baas P; Van Meerbeeck J; Fennell DA
    Eur J Cancer; 2012 Nov; 48(16):2983-92. PubMed ID: 22704893
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
    O'Brien ME; Gaafar RM; Popat S; Grossi F; Price A; Talbot DC; Cufer T; Ottensmeier C; Danson S; Pallis A; Hasan B; Van Meerbeeck JP; Baas P
    Eur J Cancer; 2013 Sep; 49(13):2815-22. PubMed ID: 23791541
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
    Zucali PA; Simonelli M; Michetti G; Tiseo M; Ceresoli GL; Collovà E; Follador A; Lo Dico M; Moretti A; De Vincenzo F; Lorenzi E; Perrino M; Giordano L; Farina G; Santoro A; Garassino M
    Lung Cancer; 2012 Mar; 75(3):360-7. PubMed ID: 21937142
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma.
    Zimling ZG; Sørensen JB; Gerds TA; Bech C; Andersen CB; Santoni-Rugiu E
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):743-54. PubMed ID: 22960937
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Is pleurectomy and decortication superior to palliative care in the treatment of malignant pleural mesothelioma?
    Zahid I; Sharif S; Routledge T; Scarci M
    Interact Cardiovasc Thorac Surg; 2011 May; 12(5):812-7. PubMed ID: 21345818
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Chemotherapy of malignant pleural mesothelioma: have we made any progress?].
    Reck M; Heigener DF; Gatzemeier U
    Zentralbl Chir; 2008 Jun; 133(3):238-42. PubMed ID: 18563688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.